Global Trends
-
Landmark Trade Agreement Shapes UK-US Pharmaceutical Market
The United Kingdom and the United States have reached a bilateral agreement to maintain zero tariffs on UK pharmaceutical shipments…
Read More » -
Sun Pharmaceutical’s updated label for Unloxcyt receives US FDA approval
The U.S. Food and Drug Administration (USFDA) has approved an updated label for Unloxcyt (cosibelimab-ipdl) for the treatment of adults…
Read More » -
Generic Drug Approval Secured for Type 2 Diabetes Treatment in the US
A pharmaceutical company has announced that it secured tentative approval from the United States Food and Drug Administration (USFDA) for…
Read More » -
Major Pharmaceutical Group Acquires Preclinical Cancer Asset
In light of substantial recent investments in oncology and mounting competition, a leading pharmaceutical corporation is seeking a new approach…
Read More » -
Novel Immunotherapy Regimen Approved for Early-Stage Gastric Cancer
The U.S. Food and Drug Administration (FDA) has granted approval for the use of Durvalumab (an immunotherapy) in combination with…
Read More » -
Expedited Review Sought for New Higher-Dose Obesity Treatment
A pharmaceutical corporation has submitted a supplemental application for a higher dose semaglutide injectable (7.2 mg) to the U.S. Food…
Read More » -
Global Strategic Restructuring: A Major Pharma Group’s Shift Toward Automation and Production Reallocation
The recent decisions by a leading Swiss pharmaceutical group highlight a broader trend within the industry: prioritizing automation, advanced manufacturing…
Read More » -
Cost-Effective Solution for Retinal Diseases Enters European Market
On November 24, 2025, in Basel, Sandoz, a global leader in affordable medicines, announced the European launch of Afqlir® (aflibercept).…
Read More » -
Sandoz Launches New Biosimilar Option in Europe
The Sandoz group has officially introduced Afqlir, its biosimilar referencing aflibercept, across various European markets. The drug received approval from…
Read More » -
US Regulator Approves Spinal Gene Therapy
The U.S. Food and Drug Administration (FDA) has approved the intrathecal (spinal injection) formulation of the gene therapy onasemnogene abeparvovec,…
Read More » -
Pharmaceutical Giant Commits Major U.S. Manufacturing Investment
The pharmaceutical corporation AstraZeneca announced a plan to invest $2 billion to expand its production capabilities within the state of…
Read More »